Research revealed that patients having non‐GCB/ABC DLBCL had higher response to lenalidomide versus the GCB/ABC subtype, predominantly due to the overactivation of NF‐kB and the higher level of interferon regulatory factor‐4 (IRF4).27, 37, 38, 39, 40. Here, NFKB1 is linked to diffuse large B-cell lymphoma.